Capstone Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capstone Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,000	Closed	-$594K	–	1605
2025 Q4	$594K	Buy	+10,000	New	+$544K	﹤0.01%	1085
2021 Q3	–	Sell	-25,000	Closed	-$2.09M	–	2007
2021 Q2	$2.09M	Sell	25,000 -42,600	-63%	-$3.38M	﹤0.01%	1009
2021 Q1	$5.1M	Sell	67,600 -2,900	-4%	-$237K	0.02%	647
2020 Q4	$6.18M	Buy	70,500 +16,000	+29%	+$1.27M	0.02%	533
2020 Q3	$4.15M	Buy	54,500 +35,000	+179%	+$3.54M	0.02%	565
2020 Q2	$2.4M	Buy	+19,500	New	+$1.94M	0.02%	651

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capstone Investment Advisors's BMRN Position: Q2 2024 in Review

Capstone Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 10,900 shares — an estimated $952K sold.

Capstone Investment Advisors first reported a position in BMRN in Q1 2015 and held it in 24 quarters. The position peaked at $3.02M in Q1 2019. 559 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

Capstone Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Capstone Investment Advisors sold 10,900 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $952K.
Capstone Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 24 quarters.
Capstone Investment Advisors's BioMarin Pharmaceuticals position peaked at $3.02M in Q1 2019.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Capstone Investment Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.